Daftar Pustaka

Abd-Elsalam SA, Noor RA, Khalaf M, Medhat MA, Karam H, Ramadan A,

Eldeen MAS, et al. (2021, May). Clinical study evaluating the efficacy of
ivermectin in COVID-19 treatment : A randomized controlled study. J Med
Virol. 2019: 10–15. doi: 10.1002/jmv.27122.

Ahmed S, Karim M, Ross A, Hossain MS, Clemens JD, Sumiya M et al. (2021).
A five-day course of ivermectin for the treatment of COVID-19 may reduce
the duration of illness. Int.j.infect.dis. 103: 214–216. doi:
10.1016/j.ijid.2020.11.191.

Alam MT, Murshed R, Bhiuyan E, Saber S, Alam RF, Robin RC. (2020, July). A
case series of 100 covid-19 positive patients treated with combination of
ivermectin and doxycycline. J. Bangladesh Coll. Phys. Surg. 38: 10–15. doi:
10.3329/jbcps.v38i0.47512.

Almazán F, Sola I, Zu S, Marquez-jurado S, Morales L, Becares M, Enjuanes L.

(2020, January). Coronavirus reverse genetic systems: infectious clones and
replicons. J. Virus Res. 189: 262–270. doi: 10.1016/j.virusres.2014.05.026.

Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. (2020). The
proximal origin of SARS-CoV-2. 2–4. doi: 10.1038/s41591-020-0820-9.

Andrew H, Anna G, Jacob L, Jonathan F, Leah E, Kaitlyn M, Victoria P, et al.

Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2
Infection. Open Forum Infect Dis. 2021 Nov; 8(11): ofab358. Published
online 2021 Jul 6. doi: 10.1093/ofid/ofab358

Bhargava A, Fukushima EA, Levine M, Zhao W, Tanveer F, Szpunar SM,

Saravolatz L. (2020). Predictors for severe covid-19 infection. J.Cid 71(8):
1962–1968. doi: 10.1093/cid/ciaa674.

Cadegiani FA, Goren A, Wambier CG, Mccoy J. (2021). Early COVID-19

therapy with azithromycin plus nitazoxanide , ivermectin or
hydroxychloroquine in outpatient settings signi fi cantly improved COVID-19
outcomes compared to known outcomes in untreated patients. J. nmni. 43:
100915. doi: 10.1016/j.nmni.2021.100915.

Caly L, Druce JD, Catton MG, Jans DA, Wagsta KM. (2020, April). The FDA-
approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
J.AntiviralRes. 178: 3–6. doi: 10.1016/j.antiviral.2020.104787.

Campbell, W. C. (1985). Ivermectin : An Update. Parasitology Today. 1:1.

Available at: https://doi.org/10.1016/0169-4758(85)90100-0.

Canga AG, Prieto AMS, Diez Liébana MJ, Martínez NF, Sierra VM, García VJJ.
(2008). The pharmacokinetics and interactions of ivermectin in humans - A
 mini-review. AAPS Journal. 10(1): 42–46. doi: 10.1208/s12248-007-9000-9.

CASP (2018). Critical appraisal skills programme Randomised Controlled Trial

Standard Checklist. Diakses dari https://casp-uk.b-cdn.net/wp-
content/uploads/2020/10/CASP_RCT_Checklist_PDF_Fillable_Form.pdf

Chaccour C, Hammann F, and Ram S. (2020). Editorial Ivermectin and COVID-

19 : Keeping Rigor in Times of Urgency. Am. J. Trop. Med. Hyg. 102(6):
1156–1157. doi: 10.4269/ajtmh.20-0271.

Chaccoura C, Casellasa A, Matteo A, Pineda I, Monterob A, Castilloa PR,

Richardsona MA, et al. (2021). The effect of early treatment with ivermectin
on viral load , symptoms and humoral response in patients with non-severe
COVID-19 : A pilot , double-blind , placebo-controlled , randomized clinical
trial. J. EClinm. 32: 100720. doi: 10.1016/j.eclinm.2020.100720.

Ciotti M, Ciccozzi M, Terrinoni A, Jiang WC, Wang CB, Bernardini S. (2020).

The COVID-19 pandemic. J. crcls. 57: 365–388.
doi:10.1080/10408363.2020.1783198

Dong L, Tian J, He S, Zhu C, Wang J, Liu C, Yang J. (2020). Possible vertical

transmission of sars-cov-2 from an infected mother to her newborn. JAMA.
doi: 10.1001/jama.2020.4621.

Elgazzar A, Eltaweel A, Youssef SA, Hany B, Hafez M, Moussa H. (2020).

Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-
19 Pandemic. J. Res. 1-10. https://doi.org/10.21203/rs.3.rs-100956/v3

Enrique L, Galan B, Melo N, Shosuka M, Melo G, Silva A, Sousa JD, et al.

(2021). Phase 2 randomized study on chloroquine , hydroxychloroquine or
ivermectin in hospitalized patients with severe manifestations of SARS-CoV-
2 infection. J. pgh. 115(4): 235–242. doi: 10.1080/20477724.2021.1890887.

Gonzalez JLB, Gámez MG, Enciso EAM, Maldonado RJE, Palacios DH, Campos
SD, Robles IO, et al. (2021). Efficacy and safety of Ivermectin and
Hydroxychloroquine in patients with severe COVID-19. A randomized
controlled trial. medRix. doi: https://doi.org/10.1101/2021.02.18.21252037

Gorial FI, Sabeeh M, Hend MS, Basim DD, Marwan MA, Adnan MA, Hassan
MA, Mohammed G, Jawad IR. (2020). Effectiveness of Ivermectin as add-on
Therapy in COVID-19 Management. MedRxiv. 2(1): 2-13 doi:
https://doi.org/10.1101/2020.07.07.20145979

Hashim A, Hashim MF, Maulood A,M. Rasheed, Dhurgham F, Fatak, Khulood K,

Kabah AS, Abdulamir. (2020). Controlled randomized clinical trial on using
Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad,
Iraq. medRxiv. doi: https://doi.org/10.1101/2020.10.26.20219345
Han Q, Lin Q, Ni Z, You L. (2020). Uncertainties about the transmission routes of
2019 novel coronavirus. J. irv. 14(4): 470–471. doi: 10.1111/irv.12735.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, et al. (2020). Articles

clinical features of patients infected with 2019 novel coronavirus in Wuhan ,
China. Elsevier Ltd. 497–506. doi: 10.1016/S0140-6736(20)30183-5.

Johns Hopkins University of Medicine COVID-19 (2021). COVID-19 Dashboard

by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins
University. Available at: https://coronavirus.jhu.edu/map.html. Diakses 2-12-
2021

Kow, C., Merchant, H.A., Mustafa, Z.U. et al. The association between the use of
ivermectin and mortality in patients with COVID-19: a meta-
analysis. Pharmacol. Rep 73, 1473–1479 (2021).
https://doi.org/10.1007/s43440-021-00245-z

Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, Azman AS, et al.
(2020). The incubation period of coronavirus disease 2019 (CoVID-19) from
publicly reported confirmed cases: Estimation and application. Annals of
Internal Medicine. 172(9):577–582. doi: 10.7326/M20-0504.

Lippi, G. and Favaloro, E. J. (2020). D-dimer is associated with severity of

coronavirus disease 2019: a pooled analysis. Journal of Thrombosis and
Haemostasis. 18(4): 844–847. doi: 10.1055/s-0040-1709650.

Liu L, Wei Q, Alvarez X, Wang H, Du Y, Zhu H, Jiang H, et al. (2011). Epithelial

cells lining salivary gland ducts are early target cells of severe acute
respiratory syndrome coronavirus infection in the upper respiratory tracts of
rhesus macaques. J. vi. 85(8): 4025–4030. doi: 10.1128/jvi.02292-10.

Long B, Brady WJ, Koyfman A, Gottlieb M. (2020). Cardiovascular

complications in COVID-19. J. ajem. 38(7): 1504–1507. doi:
10.1016/j.ajem.2020.04.048.

López-Medina E, López P, Hurtado IC, Davalos DM, Ramirez O, Martinez E,

Diazgranados JA. et al. (2021). Effect of Ivermectin on Time to Resolution of
Symptoms Among Adults With Mild COVID-19: A Randomized Clinical
Trial. JAMA. 325(14):1426–1435. doi:10.1001/jama.2021.3071

Lu CW, Liu XF, and Jia ZF. (2020, January).2019-nCoV transmission through the
ocular surface must not be ignored. doi: 10.1016/S0140-6736(20)30313-5.

Mills E. Early Treatment of COVID-19 with Repurposed Therapies: The

TOGETHER Adaptive Platform Trial. 2021. Available
from: https://rethinkingclinicaltrials.org/news/august-6-2021-early-treatment-
of-covid-19-with-repurposed-therapies-the-together-adaptive-platform-trial-
 edward-mills-phd-frcp/. Accessed 20 Desember 2021.

Mohan A, Tiwari P, Menon T, Mittal S, Patel A, Jain A, Velpandian T, et al.

(2021, August). Single-dose oral ivermectin in mild and moderate COVID-19
( RIVET-COV ): A single-centre randomized , placebo-controlled trial. J.jiac.
2: 1–7. doi: 10.1016/j.jiac.2021.08.021.

Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, Atkins D, et al.

(2009). Preferred reporting items for systematic reviews and meta-analyses:
The PRISMA statement. PLoS Medicine, 6(7). doi:
10.1371/journal.pmed.1000097.

Murti B. (2018). Prinsip dan Metode Riset Epidemiologi Edisi ke Empat.

Surakarta: Universitas Sebelas Maret

Shakhsi Niaee M, Namdar P, Allami A, Zolghadr L, Javadi A, Karampour A,

Vernasari M, et al. (2021) Ivermectin as an adjunct treatment for hospitalized
adult COVID-19 patients: A randomized multi-center clinical trial. Asian Pac
J Trop Med.14(6): 266-273. doi: 10.4103/1995-7645.318304

Okumu N, Çetinkaya A, Güner R, Ya İ, Orhan S. (2021). Evaluation of the

effectiveness and safety of adding ivermectin to treatment in severe COVID-
19 patients. 1–11. BMC infect. dis. doi: 10.1186/s12879-021-06104-9.

Pedoman Tatalaksana COVID-19 (2022) Pedoman Tatalaksana COVID-19 Edisi

4. Jakarta: Perhimpunan Dokter Paru Indonesia(PDPI), Perhimpunan Dokter
Spesialis Kardiovaskular Indonesia (PERKI), Perhimpunan Dokter Spesialis
Penyakit Dalam Indonesia (PAPDI), Perhimpunan Dokter Anestesiologi dan
Terapi Intensid Indonesia (PERDATIN), Ikatan Dokter Anak Indonesia
(IDAI).

Rajter JC, Sherman MS, and Fatteh N. (2021). Use of Ivermectin Is Associated
With Lower Mortality in Hospitalized Patients With Coronavirus Disease
2019 The Ivermectin in COVID Nineteen Study. CHEST. 159(1): 85–92. doi:
10.1016/j.chest.2020.10.009.

Ravikirti, Roy R, Pattadar C, Raj R, Argawal N, Biswas B, Majhi PK, et al.

(2021). Ivermectin as a potential treatment for mild to moderate COVID-19 –
A double blind randomized placebo-controlled trial. medRxiv. doi:
https://doi.org/10.1101/2021.01.05.21249310

Sanna G, Serrau G, Bassareo PP, Neroni P, Fanos V, Marcialis MA. (2020).

Children’s heart and COVID-19: Up-to-date evidence in the form of a
systematic review. European J.Ped. doi: 10.1007/s00431-020-03699-0.

Satuan Tugas COVID-19 (2021) Peta Sebaran COVID-19 Di Indonesia, Dasbor

COVID-19 oleh Pusat Satuan Tugas COVID-19 Indonesia. Available at:
 https://covid19.go.id/peta-sebaran-covid19.

Shahbaznejad L, Davoudi A, Eslami G, Markowitz JS, Navaeifar MR,

Hosseinzadeh F, Movahedi FS, et al. (2021). Effects of ivermectin in patients
with COVID-19 : a multicenter , double-blind , randomized , controlled
clinical trial. Clinical Therapeutics. xxx(xxx). doi:
10.1016/j.clinthera.2021.04.007.

Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C,

et al. (2020). Ivermectin to prevent hospitalizations in patients with COVID-
19 (IVERCOR-COVID19): a structured summary of a study protocol for a
randomized controlled trial. BMC infect. dis. 10–13. doi: 10.1186/s13063-
020-04813-1.

Vicenzi E, Canducci F, Pinna D, Mancini N, Carletti S, Lazzarin A, Bordignon C,

et al. (2004). Coronaviridae and SARS-associated coronavirus strain HSR1.
J. eid. 10(3). doi: 10.3201/eid1003.030683.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, et al. (2020). Clinical

Characteristics of 138 Hospitalized PatientsWith 2019 Novel Coronavirus–
Infected Pneumonia in Wuhan, China. JAMA. 11: 1061–1069. doi:
10.1001/jama.2020.1585.

WHO (2021). Coronavirus disease (COVID-19), Dashboard at WHO. Available

at: https://covid-19.who.int/.Diakses 2-12-21

Yavuzi SŞ and Çelikyurt İK. (2021). An update of anti-viral treatment of COVID-

19. Turk J Med Sci. 51: 3372-3390. doi:10.3906/sag-2106-250

Zhao S, Lin Q, Ran J, Musa SS, Yang G. (2020, January). Preliminary estimation
of the basic reproduction number of novel coronavirus (2019-nCoV) in
China, from 2019 to 2020: A data-driven analysis in the early phase of the
outbreak. Int.j.infect.dis. 92:214–217. doi: 10.1016/j.ijid.2020.01.050.